.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Federal Trade Commission
Harvard Business School
Covington
AstraZeneca
McKinsey
QuintilesIMS
Dow
Fish and Richardson

Generated: June 28, 2017

DrugPatentWatch Database Preview

ULTIVA Drug Profile

« Back to Dashboard

Which patents cover Ultiva, and what generic Ultiva alternatives are available?

Ultiva is a drug marketed by Mylan Institutional and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ULTIVA is remifentanil hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the remifentanil hydrochloride profile page.

Summary for Tradename: ULTIVA

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list17
Clinical Trials: see list81
Patent Applications: see list214
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ULTIVA at DailyMed

Pharmacology for Tradename: ULTIVA

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-001Jul 12, 1996RXYesNo5,866,591*PED► SubscribeY► Subscribe
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-002Jul 12, 1996RXYesNo5,866,591*PED► SubscribeY► Subscribe
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-003Jul 12, 1996RXYesYes5,866,591*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ULTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-002Jul 12, 19965,466,700*PED► Subscribe
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-003Jul 12, 19965,466,700*PED► Subscribe
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-001Jul 12, 19965,019,583*PED► Subscribe
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-002Jul 12, 19965,019,583*PED► Subscribe
Mylan Institutional
ULTIVA
remifentanil hydrochloride
INJECTABLE;INJECTION020630-003Jul 12, 19965,019,583*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ULTIVA

Drugname Dosage Strength RLD Submissiondate
remifentanil hydrochloridefor Injection1 mg/vial, 2 mg/vial and 5 mg/vialUltiva12/27/2013
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
US Department of Justice
Cerilliant
Fuji
Boehringer Ingelheim
Medtronic
Chinese Patent Office
Healthtrust
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot